Browsing Tag
Innovent Biologics
33 posts
Innovent Biologics strengthens mazdutide’s global credibility as Phase 3 diabetes trials land in Nature
Innovent Biologics, Inc. lands back-to-back Nature Phase 3 wins for mazdutide in type 2 diabetes. See what it means for HKEX: 01801.
Mazdutide phase 1b results from Innovent Biologics offer new hope for adolescent obesity in China
Find out how Innovent Biologics’ mazdutide trial could change adolescent obesity treatment in China—phase 3 launch is next.
Innovent Biologics launches clinical trial for IBI3011 to target gout and inflammatory diseases in China
Find out how Innovent Biologics is targeting unmet needs in gout with IBI3011, a first-in-class anti-IL-1RAP antibody now in clinical trials. Read more.
Innovent Biologics achieves key milestone as PECONDLE delivers sustained efficacy in Phase 3 psoriasis trial
Find out how Innovent’s PECONDLE is redefining long-term psoriasis care with sustained response and quarterly dosing.
Can Innovent’s PECONDLE rewrite China’s psoriasis treatment playbook with its IL-23p19 antibody?
Innovent Biologics wins NMPA nod for PECONDLE, China’s first IL-23p19 psoriasis biologic. Learn how this reshapes autoimmune therapy options for millions.
Innovent Biologics hits 20% weight loss in Phase 3: Will mazdutide become China’s Ozempic?
Mazdutide 9 mg achieves 20.08% weight loss in pivotal Chinese Phase 3 study. Learn what this means for Innovent Biologics’ NDA plans and obesity treatment.
Why Innovent Biologics and SanegeneBio believe IBI3016 could change hypertension treatment
Innovent Biologics and SanegeneBio reveal strong Phase 1 data for IBI3016 at AHA 2025. Discover how this RNAi therapy could redefine hypertension treatment.
Innovent Biologics secures FDA greenlight for first global Phase 3 trial of IBI363 in lung cancer
Innovent Biologics wins FDA approval for its first global Phase 3 trial of IBI363 in lung cancer, signaling a major milestone in immuno-oncology.
China NMPA accepts NDA for Innovent and HUTCHMED’s sintilimab-fruquintinib combo in advanced renal cell carcinoma
Innovent Biologics (HKEX: 01801) and HUTCHMED (NASDAQ: HCM) secure NDA acceptance in China for sintilimab-fruquintinib in RCC, signaling oncology market shift.
Phase 3 trials to watch in 2025: Why this year matters for biotech investors
Explore the top Phase 3 trials of 2025 from Eli Lilly, GSK, and Innovent Biologics — including pipeline impact, investor sentiment, and regulatory milestones.